Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Various substitution mutations in ALK2, a transmembrane serine/threonine kinase receptor for bone morphogenetic proteins (BMPs), have been identified in patients with genetic disorders such as fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) and heart defects. In this study, we characterized the ALK2 mutants R258G, G328V and F246Y, which were identified in patients with severe FOP, DIPG and unusual hereditary skeletal dysplasia, respectively. Both R258G and G328V were gain-of-function mutations, but F246Y was equivalent to wild-type ALK2. We also examined the effect of the suppressor FKBP12 on the signal transduction of a further 14 ALK2 mutations associated with FOP and/or DIPG. To varying extents FKBP12 over-expression suppressed the basal signaling induced by thirteen of the ALK2 mutants, whereas PF197-8L was uniquely resistant. In the PF197-8L mutant, the modelled ALK2 residue L197 induced a steric clash with the D36 residue in FKBP12 and dissociated their interaction. The co-expression of BMP type II receptors or stimulation with ligands relieved the suppression by FKBP12 by disrupting the interaction between mutant ALK2 and FKBP12. Taken together, FKBP12 binds to and suppresses mutant ALK2 proteins associated with FOP and DIPG, except for PF197-8L.

Original publication

DOI

10.1016/j.bone.2018.03.015

Type

Journal article

Journal

Bone

Publication Date

06/2018

Volume

111

Pages

101 - 108

Keywords

Activin receptor-like kinase 2 (ALK2), Bone morphogenetic proteins (BMPs), Diffuse intrinsic pontine glioma (DIPG), FKBP12, Fibrodysplasia ossificans progressiva (FOP), Heterotopic ossification, Signal transduction, Activin Receptors, Type I, Animals, Bone Diseases, Developmental, Bone Morphogenetic Protein Receptors, Type II, Bone Morphogenetic Proteins, Brain Stem Neoplasms, Cell Line, Glioma, Humans, Mice, Myositis Ossificans, Ossification, Heterotopic, Signal Transduction, Tacrolimus Binding Protein 1A